Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 7 Wilms Tumor 1 Testicular Germ Cell Tumor 1 Prostate Cancer Metastatic 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic cancer, adult 1 Ovarian Neoplasms 1 Neoplasms 1 Lung Neoplasms 1 Kidney Neoplasms 1 Hepatic Veno-Occlusive Disease 1 Glioblastoma 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1

Interventions

Sunitinib 145 Nivolumab 144 pembrolizumab 132 Sorafenib 84 Bevacizumab 77 Everolimus 74 cabozantinib 71 pazopanib 65 Axitinib 65 Ipilimumab 62 aldesleukin 52 Magnetic Resonance Spectroscopy 45 Cyclophosphamide 40 Interleukin-2 38 lenvatinib 37 Specimen Handling 36 Radiosurgery 36 Interferon-alpha 32 atezolizumab 30 temsirolimus 27 belzutifan 24 Gemcitabine 23 fludarabine phosphate 22 avelumab 22 Radiotherapy 19 Interferon alpha-2 19 Biopsy 18 fludarabine 17 durvalumab 17 Nephrectomy 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Renal Cell × Hematologic Tests × Genitourinary × Clear all

NCT04113486 2020-11-24

ENRC

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡